Celovec (EUUS7001): Why Invest Further in Evotec? Evotec stands out as one of the few companies that truly grasps the intricacies of the biotech business model. Under Werner Lanthaler’s leadership, the company has honed in on key strategic elements:  1.    Diversifying Assets: Evotec has built a robust pipeline of assets, reducing the high failure risk associated with biotech ventures.  2.    Collaborative Partnerships: By partnering with pharmaceutical companies, Evotec negotiates full cost coverage with additional upside through milestone payments and royalties as drug candidates advance. 3.    Solving a Core Problem: The focus remains on one significant goal—delivering de-risked clinical candidates, a challenge Evotec is uniquely positioned to tackle. 4.    Global Research Network: Evotec connects with leading research institutions worldwide, enhancing its innovation pipeline and R&D capabilities. In contrast to most biotech companies—many of which are single-asset ventures with a 99% failure rate or service-oriented businesses that rely solely on project fees—Evotec combines the best of both worlds. It operates with the financial stability of a service business (thanks to early-stage cost coverage from pharma partners) while securing long-term upside through royalties and milestone payments. With IP secured on Evotec’s side, the company can fully capitalize on its innovations. Additionally, Evotec’s model fosters long-term relationships, adding stability and predictability. At this price point, as long as the company continues executing on its business model, significant value creation seems inevitable. This is why I recently increased my position in Evotec. (13.11. 09:26)